ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
For a plant that has been used for millennia, controls on the supply of psychoactive and non-psychoactive components extracted from cannabis are relatively recent, with global regulations starting in the 20th century with the International Opium Conventions. The current, and often conflicting, regulatory landscape has focused on definitions of hemp and cannabidiol (CBD). Reference materials are critical to defining the % ?9-THC in these products.
Ultra-low freezers, or ULTs, are specialised refrige-rating equipment created to store vaccines, medicines, and samples at ultra-low temperatures. By offering storage temperatures ranging from -20°C to -86°C and energy efficiency, B Medical Systems’ ULTs create an ideal environment for the long-term storage of extremely temperature-sensitive biologicals, making its products perfect for use in laboratory or clinical environments.
Lonza will expand its production capacity of Moderna’s mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands.
The European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2).
Senti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.
German-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG.
|
|
|
||
Life science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre clinical trials.
Isolating cells from whole blood or LRS cones carries the risk of red blood cell (RBC) contamination, which can have deleterious effects on downstream cell cultures.
Adeno-associated viruses (AAV) have revolutionised gene therapies as safe and effective gene shuttles. The growing demand for AAV vectors now requires an industrialised process throughout pre-clinical development that involves comprehensive monitoring from production to patient to ensure safety and efficacy of the therapeutic agent and reduce cost of goods.
APEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.